Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer

Lu Zhang, Panayotis C. Theodoropoulos, Ugur Eskiocak, Wentian Wang, Young Ah Moon, Bruce Posner, Noelle S. Williams, Woodring E. Wright, Sang Bum Kim, Deepak Nijhawan, Jef K. De Brabander, Jerry W. Shay

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Mutations in the adenomatous polyposis coli (APC) gene are common in colorectal cancer (CRC), and more than 90% of those mutations generate stable truncated gene products. We describe a chemical screen using normal human colonic epithelial cells (HCECs) and a series of oncogenically progressed HCECs containing a truncated APC protein. With this screen, we identified a small molecule, TASIN-1 (truncated APC selective inhibitor-1), that specifically kills cells with APC truncations but spares normal and cancer cells with wild-type APC. TASIN-1 exerts its cytotoxic effects through inhibition of cholesterol biosynthesis. In vivo administration of TASIN-1 inhibits tumor growth of CRC cells with truncated APC but not APC wild-type CRC cells in xenograft models and in a genetically engineered CRC mouse model with minimal toxicity. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC. 2016

Original languageEnglish (US)
Article number361ra140
JournalScience Translational Medicine
Volume8
Issue number361
DOIs
StatePublished - Oct 19 2016

Fingerprint

Adenomatous Polyposis Coli
Colorectal Neoplasms
Adenomatous Polyposis Coli Protein
Epithelial Cells
APC Genes
Mutation
Heterografts
Neoplasms
Cholesterol
Growth
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. / Zhang, Lu; Theodoropoulos, Panayotis C.; Eskiocak, Ugur; Wang, Wentian; Moon, Young Ah; Posner, Bruce; Williams, Noelle S.; Wright, Woodring E.; Kim, Sang Bum; Nijhawan, Deepak; De Brabander, Jef K.; Shay, Jerry W.

In: Science Translational Medicine, Vol. 8, No. 361, 361ra140, 19.10.2016.

Research output: Contribution to journalArticle

Zhang, Lu ; Theodoropoulos, Panayotis C. ; Eskiocak, Ugur ; Wang, Wentian ; Moon, Young Ah ; Posner, Bruce ; Williams, Noelle S. ; Wright, Woodring E. ; Kim, Sang Bum ; Nijhawan, Deepak ; De Brabander, Jef K. ; Shay, Jerry W. / Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. In: Science Translational Medicine. 2016 ; Vol. 8, No. 361.
@article{3e47285a5b2e4291bc490aefe21cb9d7,
title = "Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer",
abstract = "Mutations in the adenomatous polyposis coli (APC) gene are common in colorectal cancer (CRC), and more than 90{\%} of those mutations generate stable truncated gene products. We describe a chemical screen using normal human colonic epithelial cells (HCECs) and a series of oncogenically progressed HCECs containing a truncated APC protein. With this screen, we identified a small molecule, TASIN-1 (truncated APC selective inhibitor-1), that specifically kills cells with APC truncations but spares normal and cancer cells with wild-type APC. TASIN-1 exerts its cytotoxic effects through inhibition of cholesterol biosynthesis. In vivo administration of TASIN-1 inhibits tumor growth of CRC cells with truncated APC but not APC wild-type CRC cells in xenograft models and in a genetically engineered CRC mouse model with minimal toxicity. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC. 2016",
author = "Lu Zhang and Theodoropoulos, {Panayotis C.} and Ugur Eskiocak and Wentian Wang and Moon, {Young Ah} and Bruce Posner and Williams, {Noelle S.} and Wright, {Woodring E.} and Kim, {Sang Bum} and Deepak Nijhawan and {De Brabander}, {Jef K.} and Shay, {Jerry W.}",
year = "2016",
month = "10",
day = "19",
doi = "10.1126/scitranslmed.aaf8127",
language = "English (US)",
volume = "8",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "361",

}

TY - JOUR

T1 - Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer

AU - Zhang, Lu

AU - Theodoropoulos, Panayotis C.

AU - Eskiocak, Ugur

AU - Wang, Wentian

AU - Moon, Young Ah

AU - Posner, Bruce

AU - Williams, Noelle S.

AU - Wright, Woodring E.

AU - Kim, Sang Bum

AU - Nijhawan, Deepak

AU - De Brabander, Jef K.

AU - Shay, Jerry W.

PY - 2016/10/19

Y1 - 2016/10/19

N2 - Mutations in the adenomatous polyposis coli (APC) gene are common in colorectal cancer (CRC), and more than 90% of those mutations generate stable truncated gene products. We describe a chemical screen using normal human colonic epithelial cells (HCECs) and a series of oncogenically progressed HCECs containing a truncated APC protein. With this screen, we identified a small molecule, TASIN-1 (truncated APC selective inhibitor-1), that specifically kills cells with APC truncations but spares normal and cancer cells with wild-type APC. TASIN-1 exerts its cytotoxic effects through inhibition of cholesterol biosynthesis. In vivo administration of TASIN-1 inhibits tumor growth of CRC cells with truncated APC but not APC wild-type CRC cells in xenograft models and in a genetically engineered CRC mouse model with minimal toxicity. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC. 2016

AB - Mutations in the adenomatous polyposis coli (APC) gene are common in colorectal cancer (CRC), and more than 90% of those mutations generate stable truncated gene products. We describe a chemical screen using normal human colonic epithelial cells (HCECs) and a series of oncogenically progressed HCECs containing a truncated APC protein. With this screen, we identified a small molecule, TASIN-1 (truncated APC selective inhibitor-1), that specifically kills cells with APC truncations but spares normal and cancer cells with wild-type APC. TASIN-1 exerts its cytotoxic effects through inhibition of cholesterol biosynthesis. In vivo administration of TASIN-1 inhibits tumor growth of CRC cells with truncated APC but not APC wild-type CRC cells in xenograft models and in a genetically engineered CRC mouse model with minimal toxicity. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC. 2016

UR - http://www.scopus.com/inward/record.url?scp=84991669873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991669873&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aaf8127

DO - 10.1126/scitranslmed.aaf8127

M3 - Article

C2 - 27798265

AN - SCOPUS:84991669873

VL - 8

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 361

M1 - 361ra140

ER -